KHKoichiro Haruki

Koichiro Haruki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koichiro Haruki has a total of 443 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer

    by Masashi Tsunematsu, Koichiro Haruki, Mitsuru Yanagaki, Yoshihiro Shirai, Ryoga Hamura, Yuto Yamahata, Tomohiko Taniai, Haruka Kobayashi, Yuna Saito, Kohei Okazaki, et al.

  • Prior cholecystectomy may identify a biologically aggressive subset of RAS-mutated proximal colon cancer: A 13-year retrospective cohort study

    by Masashi Tsunematsu, Koichiro Haruki, Mitsuru Yanagaki, Yoshihiro Shirai, Yoshiaki Tanji, Shinji Onda, Tomohiko Taniai, Michinori Matsumoto, Kenei Furukawa, Toru Ikegami

  • Preoperative prediction of vessels encapsulating tumor clusters in hepatocellular carcinoma based on CT findings and des-γ-carboxy prothrombin level

    by Tomohiko Taniai, Koichiro Haruki, Megumi Shiraishi, Kenei Furukawa, Mitsuru Yanagaki, Kazutaka Gomisawa, Juha P. Väyrynen, Yuto Yamahata, Munetoshi Akaoka, Masashi Tsunematsu, et al.

    Background Vessels encapsulating tumor clusters (VETC) has been associated with poor prognosis in hepatocellular carcinoma (HCC). However, the preoperative prediction of VETC remains insufficient. We established the VETC predictive score based on CT findings and clinical data in patients with HCC. Methods A total of 209 patients were enrolled, and we investigated clinical features and computed tomography (CT) findings in patients with VETC-positive HCC. The preoperative VETC predictive score was established based on the odds ratios calculated by logistic regression analysis using identified predictive factors, and the accuracy of this score was investigated. The utility of VETC predictive score was validated in the validation cohort. Results VETC-positive HCC was associated with higher protein induced by des-γ-carboxy prothrombin (DCP) level (p = 0.03), larger tumor size (p < 0.01), intratumor necrosis (p < 0.01), and intratumor vessels (p < 0.01), and the VETC predictive score was established using these variables. The positive rate of VETC was significantly higher in the score-high group compared to the score-low group (60% vs. 27%, p < 0.01). Patients with high scores showed higher DCP level (p < 0.01), moderate/poor differentiation (p < 0.01), larger tumor (p < 0.01), microvascular invasion (p < 0.01), VETC-positivity (p < 0.01), lower densities of CD8+ cells in center of tumor and invasive margin (p < 0.01, and p < 0.01, respectively), intratumor necrosis (p < 0.01), and intratumor vessels (p < 0.01). In the validation cohort, the high VETC predictive score was associated with VETC-positivity (54% vs. 20%, p < 0.01). Conclusion The VETC predictive score based on CT and DCP is useful, and preoperative diagnosis of VETC may contribute to optimized treatment management for HCC.

  • Tumor Endothelial Cell‐Derived Extracellular Vesicles Promote Hepatocellular Carcinoma Progression Through Intercellular Interaction Via miRNA

    by Mitsuru Yanagaki, Koichiro Haruki, Munetoshi Akaoka, Hoshiho Kubota, Yu Fujita, Masayuki Shimoda, Kenei Furukawa, Shinji Onda, Yoshihiro Shirai, Tomohiko Taniai, et al.

    Aim: The aim of this study was to determine whether the interaction of HCC cells and tumor endothelial cells (TECs) via extracellular vesicle (EV) is involved in the progression of HCC. Methods: Five sets of matched HCC and adjacent tissues were collected from patients with primary HCC who underwent liver resections. The TECs and normal endothelial cells (NECs) were isolated with magnetic selection of CD31 + cells. Condition medium (CM) and EV derived from NECs and TECs were co‐cultured with the human HCC cell lines. miRNA sequencing analysis was performed to characterize the miRNA profiles of EVs. Additionally, the relationships between prognosis and miRNA targeted proteins in HCC tissues were analyzed among 121 HCC patients. Results: Both TECs and NECs exhibited high expression levels of CD31 protein. In tube‐forming assays, NECs and TECs formed round tubes characteristic of cultured endothelial cells. Functional assays revealed that TEC‐derived CM and EV markedly enhanced migration and invasiveness in HCC cells, whereas NEC‐derived CM and EV showed minimal effects. miR‐142‐3p was significantly upregulated in TECs‐derived EVs, which reduced RHOBTB3 expression and promoted HCC migration and invasiveness. miR‐20a‐5p was significantly downregulated in TECs‐derived EVs, which increased ITGB8 expression and promoted HCC migration and invasiveness. Furthermore, low RHOBTB3 and high ITGB8 expression in HCC tissues were significant risk factors for recurrence and survival in HCC patients. Conclusions: TECs‐derived EV accelerate HCC progression through intercellular interaction via miRNA, suggesting that TECs can be potential therapeutic target in HCC patients.

  • Incidental intrahepatic cholangiocarcinoma detected in the explant liver after living-donor liver transplantation for polycystic liver disease

    by Satoshi Asanuma, Koichiro Haruki, Kenei Furukawa, Shinji Onda, Yoshihiro Shirai, Michinori Matsumoto, Tomohiko Taniai, Masashi Tsunematsu, Mitsuru Yanagaki, Toru Ikegami

    Living-donor liver transplantation (LDLT) is considered for polycystic liver disease (PLD) with portal hypertension or quality of life deterioration. However, concomitant malignant tumors are extremely rare in PLD. The recipient was a 68-year-old female who had been followed for PLD. She developed progressive jaundice with ascites and lower leg edema. Computed tomography revealed portal hypertension with intrahepatic portal vein stenosis and splenorenal shunt. The liver was replaced by numerous cysts, but no obvious tumorous lesions were identified. Tumor markers were CEA of 7.9 ng/ml and CA19-9 of 420 U/ml. With a MELD score of 12 and Child-Pugh grade C, LDLT was planned. The living liver donor was her 42-year-old daughter, and a right lobe graft was planned for the transplantation with predicted graft-to-recipient weight ratio (GRWR) of 0.88. Portal inflow modulation was performed with proximal splenic artery embolization before LDLT. The operation time was 351 min and the intraoperative blood loss was 2,100 ml. The recipient was discharged on postoperative day 17 without any complications. Although no macroscopic tumor was observed in the explanted liver, histopathological examination revealed adenocarcinoma with papillary proliferation in the cyst wall containing hematoma. Biliary intraepithelial neoplasia (BilIN-1) was also found in the adjacent cysts. The recipient remains well without recurrence with good graft function at 2.5 years after LDLT. We herein report an extremely rare case of incidental intrahepatic cholangiocarcinoma detected in the explanted liver after LDLT for PLD. The possibility of concomitant malignant tumor should be considered even in PLD.

  • Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐ EOB ‐ DTPA ‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma

    by Munetoshi Akaoka, Koichiro Haruki, Jun Woo, Kazuyoshi Ohki, Kenei Furukawa, Shinji Onda, Masashi Tsunematsu, Michinori Matsumoto, Yoshihiro Shirai, Toru Ikegami

    Background: Hepatobiliary phase (HBP) findings on Gd‐EOB‐DTPA‐enhanced MRI (EOB‐MRI) have been proposed as biomarkers of hepatocellular carcinoma (HCC). However, the association between intratumor signal heterogeneity in HBP of EOB‐MRI and survival or tumor microenvironment remains unclear. Methods: We retrospectively analyzed 167 patients who underwent hepatic resection for HCC. The coefficient of variation (CV) in HBP on preoperative EOB‐MRI was calculated as the standard deviation/mean of the intratumor signal intensity. Hyperintense area (HIA) was defined as tumor regions with signal intensity equal to or higher than the surrounding parenchyma. Associations of imaging‐defined heterogeneity (high CV with HIA) with survival and immune infiltration were evaluated. Results: Multivariate analyses showed male, negative HBs‐antigen, elevated PIVKA‐II, multiple tumors, microvascular invasion, and high CV with HIA (all p < 0.05) were significant predictors of disease‐free survival, while negative HBs‐antigen, elevated PIVKA‐II, microvascular invasion, and high CV with HIA (all p < 0.05) were significant predictors of overall survival. High CV with HIA correlated with male ( p = 0.04), larger tumor size ( p < 0.01), multiple tumors ( p < 0.01), and less CD8 + T‐cell infiltration into tumor center ( p = 0.03) and invasive margin ( p = 0.048). Conclusions: High CV with HIA in HBP of EOB‐MRI may serve as a novel prognostic imaging biomarker after resection and reflect an immune‐cold HCC microenvironment.


  • Open Access

    Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12‐Year Retrospective Cohort Study of 3487 Consecutive Patients

    by Masashi Tsunematsu, Koichiro Haruki, Kazuhiro Yanamoto, Takuo Takehana, Shunta Ishizaki, Mitsuru Yanagaki, Yoshihiro Shirai, Kenei Furukawa, Shinji Onda, Toru Ikegami

    Background: The prognostic impact of prior cholecystectomy (CCY) in patients with colorectal cancer (CRC) remains uncertain. The aim of this study was to evaluate the prognostic impact of prior CCY in a large cohort of patients with CRC, with particular attention to tumor location. Methods: We retrospectively analyzed all patients diagnosed with colorectal adenocarcinoma between January 2012 and December 2023. Patients were classified into proximal (cecum, ascending, and transverse) and distal (descending, sigmoid, and rectum) groups. Survival outcomes were compared using multivariate Cox proportional hazards regression models, including an interaction term between tumor location and history of CCY. Propensity score matching (PSM) was performed as a sensitivity analysis. Results: Among 3487 patients (1375 proximal and 2112 distal CRC), 158 (4.8%) had a history of CCY. Proximal CRC was more frequently associated with female sex, older age, history of CCY, poor differentiation, BRAF mutation, MSI‐high status, and non‐resection initial strategy ( p ≤ 0.005). Among proximal CRC patients, multivariate analysis revealed TNM stage III/IV ( p < 0.001), non‐resection initial strategy ( p < 0.001), and history of CCY ( p = 0.042) were independent predictors of poor overall survival (OS). Prior CCY was associated with worse OS in proximal CRC ( p = 0.004). A significant interaction between tumor location and history of CCY was observed ( p for interaction = 0.025). Conclusions: History of CCY was associated with worse prognosis in proximal CRC but not in distal CRC, suggesting a differential impact of CCY on prognosis in CRC. Our findings would provide insight into further research on bile acid metabolism or microbiome modulation in CRC patients.


  • Open Access

    Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

    by Koichiro Haruki, Kenei Furukawa, Munetoshi Akaoka, Yuto Yamahata, Shinji Onda, Yoshihiro Shirai, Masashi Tsunematsu, Tomohiko Taniai, Michinori Matsumoto, Toru Ikegami

    Background: Oncological resectability classification for hepatocellular carcinoma (HCC) emphasizes the need to reassess treatment strategies for borderline resectable (BR) cases. This study evaluated surgical outcomes and prognostic factors in BR‐HCC and reconsidered multidisciplinary approaches for recurrence management. Methods: The study comprised 433 patients who underwent primary hepatic resection for HCC between 2000 and 2023. Patients were classified as R, BR1, and BR2 according to the Expert Consensus Statement 2023. Multivariate Cox proportional hazard models were conducted to identify prognostic factors for disease‐free and overall survival in BR (BR1 + BR2) patients. Results: Among 70 patients with BR‐HCC (BR1: n = 37, BR2: n = 33), 5‐year overall survival was 53% in BR1 versus 22% in BR2 patients ( p = 0.06). In multivariate analysis, up‐to‐7 out ( p < 0.001) and lymph node metastasis ( p < 0.001) were independent predictors of cancer recurrence, whereas anatomical resection was associated with improved disease‐free survival ( p = 0.02). Independent predictors of overall survival included older age ( p = 0.01), Child‐Pugh B ( p < 0.001), up‐to‐7 out ( p = 0.01), macrovascular invasion ( p = 0.01), and lymph node metastasis ( p < 0.001). Recurrence occurred in 89% of BR‐HCC patients, with BR2 showing more frequent early recurrence within 1 year ( p = 0.006) and recurrence beyond Milan criteria ( p = 0.02) compared to BR1. Patients receiving surgical resection or radiofrequency ablation for recurrence demonstrated better survival compared with other treatments ( p < 0.001). Conclusions: BR1 and BR2‐HCC represent biologically aggressive subsets with high recurrence rates and poor prognosis, particularly in tumors with up‐to‐7 out status, lymph node metastasis, and macrovascular invasion. Active salvage treatment for recurrence may improve survival, highlighting the importance of multidisciplinary approaches in BR‐HCC management.

  • Open Access

    Supplementary Figure S7 from T-cell Subset Features and Distributions Evolve across the Colorectal Precancer–Cancer Spectrum

    by Yasutoshi Takashima, Andressa Dias Costa, Naohiko Akimoto, Tomotaka Ugai, Phoenix Bell, Juha P. Väyrynen, Jason L. Hornick, Mari Mino-Kenudson, Yuxue Zhong, Satoko Ugai, et al.

    Supplementary Figure S7. (A-D) Density of CD3+CD4+ and CD3+CD8+ T cells in intraepithelial and lamina propria propria/stromal regions across normal mucosa, non-serrated and serrated precursors, and carcinoma stratified by American Joint Committee on Cancer (AJCC) stage and mismatch repair (MMR) status. P values were calculated with Mann-Whitney U test (Wilcoxon rank-sum test) as compared to colorectal normal mucosa near precursor lesions (normal), carcinoma with AJCC stage II-IV (CA stage II-IV), and carcinoma with proficient mismatch repair (CA pMMR). ***: P <0.0005, **: P <0.005, *: P <0.05. Abbreviations: AJCC, American Joint Committee on Cancer; CA, colorectal invasive carcinoma; Carcinoma stage I, colorectal carcinoma with AJCC stage I; Carcinoma stage II-IV, colorectal carcinoma with AJCC stage II-IV; dMMR, deficient mismatch repair; Non-serrated, non-serrated adenomas, Normal, colorectal normal mucosa near precursor lesions; pMMR, proficient mismatch repair; Serrated, serrated lesions.